Chemotherapy-induced neutropenia (CIN) is a common side effect of cancer treatment that occurs when the number of neutrophils, a type of white blood cell, decreases due to chemotherapy.

Chemotherapy-induced neutropenia Market can lead to severe complications, such as infections and fever, which may require hospitalization and interruption of cancer treatment. The growing incidence of cancer worldwide has led to an increased demand for effective CIN treatment options, including granulocyte colony-stimulating factors (G-CSFs) and antibiotics. These treatments help to reduce the duration and severity of neutropenia, allowing patients to continue their chemotherapy regimens without interruption.

According to CoherentMI, The chemotherapy induced neutropenia (CIN) market is estimated to be valued at USD 14.88 Bn in 2025 and is expected to reach USD 21.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Key Takeaways:

1. Key players in the Chemotherapy Induced Neutropenia Treatment Market are focusing on the development of novel and innovative treatment options to address the growing demand for effective CIN management. Companies such as Amgen Inc., Novartis AG, and Teva Pharmaceutical Industries Ltd. are investing in research and development to expand their product portfolios and maintain their market position. These key players are also engaging in strategic collaborations and partnerships to accelerate the development and commercialization of new CIN treatments.

Get More Insights On: Chemotherapy-induced neutropenia Market

Get this Report in Japanese Language: :  化学療法誘発性好中球減少症（CIN）市場

Get this Report in Korean Language:  화학요법유도호중구감소증(CIN)시장